ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelicBecn1loss by Lozy, Fred et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=kaup20
Autophagy
ISSN: 1554-8627 (Print) 1554-8635 (Online) Journal homepage: https://www.tandfonline.com/loi/kaup20
ERBB2 overexpression suppresses stress-induced
autophagy and renders ERBB2-induced mammary
tumorigenesis independent of monoallelic Becn1
loss
Fred Lozy, Xiaofeng Cai-McRae, Irina Teplova, Sandy Price, Anupama Reddy,
Gyan Bhanot, Shridar Ganesan, Alexei Vazquez & Vassiliki Karantza
To cite this article: Fred Lozy, Xiaofeng Cai-McRae, Irina Teplova, Sandy Price, Anupama
Reddy, Gyan Bhanot, Shridar Ganesan, Alexei Vazquez & Vassiliki Karantza (2014) ERBB2
overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary
tumorigenesis independent of monoallelic Becn1 loss, Autophagy, 10:4, 662-676, DOI: 10.4161/
auto.27867
To link to this article:  https://doi.org/10.4161/auto.27867
Copyright © 2014 Landes Bioscience View supplementary material 
Published online: 30 Jan 2014. Submit your article to this journal 
Article views: 813 View related articles 
View Crossmark data Citing articles: 11 View citing articles 
Autophagy 10:4, 662–676; April 2014; © 2014 Landes Bioscience
662 Autophagy Volume 10 Issue 4
 TrAnsLATIonAL reseArch PAPerTrAnsL TIonA  eseArch PAPer
*Correspondence to: Vassiliki Karantza; Email: karantva@cinj.rutgers.edu
Submitted: 06/21/2013; Revised: 01/12/2014; Accepted: 01/14/2014
http://dx.doi.org/10.4161/auto.27867
ERBB2 overexpression suppresses stress-induced 
autophagy and renders ERBB2-induced  
mammary tumorigenesis independent  
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Abbreviations: AKT1, v-akt murine thymoma viral oncogene homolog 1; ATG, autophagy-related; BA, basal-like;  
BafA1, bafilomycin A
1
; BCL2, B-cell CLL/lymphoma 2; BECN1, Beclin 1; CASP3, caspase 3; CQ, chloroquine; EGFP, enhanced 
green fluorescent protein; EM, electron microscopy; ER, estrogen receptor; RB1CC1/FIP200, RB1-inducible coiled-coil 1;  
ERBB2, v-erb-b2 avian erythoblastic leukemia viral oncogene homolog 2; ERBB3, v-erb-b2 avian erythroblastic leukemia viral 
oncogene homolog 3; ERBB4, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 4; IHC, immunohistochemistry; 
iMMECs, immortalized mouse mammary epithelial cells; MAP1LC3B (LC3B), microtubule-associated protein 1 light chain 3 
beta; MAPK1, mitogen-activated protein kinase 1; MAPK3, mitogen-activated protein kinase 3; MG, mammary gland; MKI67, 
marker of proliferation Ki-67; MMTV, mouse mammary tumor virus; PALB2, partner and localizer of BRCA2;  
PI3K, phosphoinositide 3-kinase; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha;  
pMMECs, primary mouse mammary epithelial cells; PTEN, phosphatase and tensin homolog; PyMT, polyoma middle T;  
RAS (KRAS and HRAS), Kirsten and Harvey rat sarcoma viral oncogene homolog; SlG, salivary gland; SQSTM1/p62, 
sequestosome 1; TOP2A, topoisomerase (DNA) II alpha 170 kDa; TP53, tumor protein 53; TZB and tzb, trastuzumab;  
UT, untreated
Defective autophagy has been implicated in mammary tumorigenesis, as the gene encoding the essential autophagy 
regulator Becn1 is deleted in human breast cancers and Becn1+/− mice develop mammary hyperplasias. In agreement 
with a recent study, which reports concurrent allelic BECN1 loss and erBB2 amplification in a small number of human 
breast tumors, we found that low BECN1 mrnA correlates with erBB2-overexpression in breast cancers, suggesting that 
BECN1 loss and erBB2 overexpression may functionally interact in mammary tumorigenesis. We now report that erBB2 
overexpression suppressed autophagic response to stress in mouse mammary and human breast cancer cells. erBB2-
overexpressing Becn1+/+ and Becn1+/− immortalized mouse mammary epithelial cells (iMMecs) formed mammary tumors 
in nude mice with similar kinetics, and monoallelic Becn1 loss did not alter erBB2- and PyMT-driven mammary tumorigen-
esis. In human breast cancer databases, erBB2-expressing tumors exhibit a low autophagy gene signature, independent 
of BECN1 mrnA expression, and have similar gene expression profiles with non-erBB2-expressing breast tumors with 
low BECN1 levels. We also found that erBB2-expressing BT474 breast cancer cells, despite being partially autophagy-defi-
cient under stress, can be sensitized to the anti-erBB2 antibody trastuzumab (tzb) by further pharmacological or genetic 
autophagy inhibition. our results indicate that erBB2-driven mammary tumorigenesis is associated with functional 
autophagy suppression and erBB2-positive breast cancers are partially autophagy-deficient even in a wild-type BECN1 
background. Furthermore and extending earlier findings using tzb-resistant cells, exogenously imposed autophagy inhi-
bition increases the anticancer effect of trastuzumab on tzb-sensitive erBB2-expressing breast tumor cells, indicating 
that pharmacological autophagy suppression has a wider role in the treatment of erBB2-positive breast cancer.
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Introduction
Autophagy is a dynamic self-catabolic cellular process, 
whereby proteins and organelles are targeted to lysosomes for 
degradation. Autophagy is upregulated during periods of stress 
and maintains cell viability by enabling basic biomolecule and 
energy recycling. Under regular growth conditions, basal auto-
phagy preserves cellular homeostasis by mediating degradation of 
misfolded proteins and aged or damaged organelles, thus mitigat-
ing cell damage.1-4
Defective autophagy has been implicated in tumorigenesis, 
as the essential autophagy gene, BECN1, is commonly deleted 
in breast, ovarian, and prostate cancers.5 BECN1 is essential for 
autophagosome formation and, when ectopically expressed in 
partially autophagy-deficient human MCF7 breast cancer cells, 
it restores functional autophagy and suppresses tumorigenesis.6 
becn1−/− mice die early in embryogenesis, while aging Becn1+/− 
mice are tumor-prone, developing lymphomas and carcinomas 
of the lung and liver.7,8 Furthermore, mammary tissues from 
Becn1+/− mice display preneoplastic, hyperproliferative changes, 
but no spontaneous mammary carcinomas.7 The seemingly par-
adoxical association between increased tumorigenesis and dys-
function and/or loss of a survival mechanism can be reconciled 
by the findings that autophagy defects render cells susceptible to 
metabolic stress and DNA damage, thus enhancing tumor necro-
sis, inflammation and genomic instability, which in turn accel-
erate tumorigenesis.4,9,10 However, autophagy may also act as a 
tumor-promoting mechanism by supporting cancer cell survival, 
as it is readily induced in hypoxic tumor regions and in response 
to chemotherapy and radiation.11-13
Although allelic BECN1 loss has been implicated in the 
pathophysiology of breast cancer,5 its specific role(s) in tumor 
initiation and progression have not been determined. A recent 
study reveals significant association between BECN1 deletion 
and ERBB2 amplification,14 thus providing evidence for lower 
BECN1 expression in a particular breast cancer subtype.15
ERBB2/HER2/neu (v-erb-b2 avian erythroblastic leukemia 
viral oncogene homolog 2) is a member of the HER family of 
tyrosine kinases, along with EGFR (epidermal growth factor 
receptor), ERBB3, and ERBB4. In normal cells, a variety of 
extracellular ligands bind to HER receptor heterodimers, lead-
ing to activation of pathways that control growth, differentiation, 
motility, and adhesion.16-20 Deregulation of these signaling net-
works occurs frequently in cancer, as exemplified by ERBB2 gene 
amplification in breast cancer and by constitutive EGFR activa-
tion in lung and colon cancers.21-25 ERBB2 overexpression results 
in aberrant signaling of the PI3K-AKT1 and MAPK1/3 path-
ways, which in turn are associated with malignant transforma-
tion,26 and ERBB2-positive breast malignancies are characterized 
by aggressive nature, poor clinical outcome, and chemother-
apy resistance.27 In addition to ERBB2 amplification, further 
genomic changes are commonly required for ERBB2-induced 
tumorigenesis, as abnormal ERBB2 signaling leads to apoptosis 
in cells carrying wild-type TP53.28,29
Interestingly, the human BECN1 and ERBB2 genes are 
both located on chromosome 17, specifically at the 17q12 and 
17q21 locuses, respectively, which are characterized by frequent 
genomic instability events, such as ERBB2-TOP2A amplification 
and allelic loss events,30-32 in human tumors. In a small number 
of breast tumors examined by fluorescence in situ hybridization, 
genomic BECN1 loss correlates with ERBB2 amplification and 
this result has been confirmed in 2 independent, public copy 
number microarray data sets.14 Furthermore, breast cancers with 
concurrent BECN1 deletion and ERBB2 amplification were also 
characterized by alterations in the TP53, PTEN, and PIK3CA 
genes.14 However, despite the reported association between 
BECN1 loss and ERBB2-positive breast cancer, the role of 
BECN1 in ERBB2-induced mammary tumorigenesis has not yet 
been investigated. Quite intriguingly, ERBB2-positive tumors 
resistant to the humanized mouse monoclonal ERBB2 antibody 
trastuzumab (tzb) upregulate basal autophagy and are resensi-
tized to treatment by autophagy inhibition,33 thus implicating 
autophagy induction in development of treatment resistance 
and the high relapse rates observed in patients with metastatic 
ERBB2-positive breast cancer.
To determine the role of BECN1 deficiency in ERBB2-positive 
breast cancer pathogenesis and treatment, we investigated the 
impact of ERBB2 overexpression on the functional status of 
autophagy in immortalized mouse mammary epithelial cells and 
human breast cancer cell lines under metabolic stress. We also 
investigated the effect of monoallelic Becn1 loss on mammary 
tumorigenesis in the MMTV-Neu and MMTV-PyMT mouse 
tumor models. We now report that ERBB2 overexpression does 
not affect basal autophagy, but suppresses stress-induced auto-
phagy in mammary tumor cells, even in a wild-type Becn1 back-
ground. Furthermore, monoallelic Becn1 deletion does not alter 
the tumorigenicity of ERBB2-expressing iMMECs in nude mice 
in vivo and does not impact spontaneous mammary tumori-
genesis in the MMTV-Neu and MMTV-PyMT mouse models. 
We also found that low BECN1 expression correlates with the 
ERBB2-positive and basal-like human breast cancer subtypes and 
that ERBB2-positive breast tumors, independently of BECN1 
mRNA levels, are likely functionally autophagy-deficient, as 
determined by gene expression profiling. Finally, both genetic 
and pharmacological autophagy inhibition enhance the response 
of tzb-sensitive, ERBB2-positive breast cancer cells to trastu-
zumab, indicating that autophagy modulation may improve the 
therapeutic efficacy of standard treatment in ERBB2-positive 
breast cancer.
Results
Low BECN1 expression correlates with ERBB2-positive and 
basal-like breast cancer subtypes
Given the recently reported association between genetic 
BECN1 loss and ERBB2 amplification in a small number of 
human breast tumors,14 we investigated larger human breast 
cancer gene profiling databases to determine whether BECN1 
expression correlates in any way with particular breast cancer 
subtypes. Using 3 independent DNA microarray databases34-36 
totaling 254 breast cancer specimens, we discovered that both 
ERBB2-positive and basal-like breast tumors commonly exhibit 
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low BECN1 expression, whereas estrogen receptor (ER)-positive 
tumors are characterized by higher BECN1 mRNA levels (Fig. 1A 
and B, P < 0.05).
ERBB2 overexpression in mammary tumor cells does not 
affect basal autophagy, but suppresses autophagy induction in 
response to metabolic stress
To examine the effect of ERBB2 overexpression on the func-
tional status of autophagy, we used our previously described 
mouse mammary epithelial cell model,37 and transfected Becn1+/+ 
and Becn1+/− iMMECs with a plasmid expressing wild-type 
human ERBB2. While the transfection efficiencies were simi-
lar for Becn1+/+ and Becn1+/− iMMECs as previously described,4 
we obtained several ERBB2-expressing Becn1+/+ iMMEC lines 
(7 out of 13 antibiotic-resistant colonies), but only one ERBB2-
expressing Becn1+/− iMMEC line (1 out of 13 antibiotic-resistant 
colonies) (Fig. 2A), possibly indicating that ERBB2 overexpres-
sion is not well tolerated in partially autophagy-deficient Becn1+/− 
iMMECs and is, thus, negatively selected for in vitro. Similar 
results were obtained when the experiment was repeated, at 
which time one more ERBB2-expressing Becn1+/− iMMEC line 
was recovered.
Given the recently documented upregulation of basal auto-
phagy in mutant RAS-expressing mouse and human cancer cell 
lines and the resultant dependence of RAS-mutant tumors on 
autophagy for growth,38 we hypothesized that the low recovery 
rate of ERBB2-expressing Becn1+/− cell lines might be secondary 
Figure 1. Low BECN1 mrnA levels correlate with the erBB2-positive and triple negative breast cancer 
subtypes. (A) relative expression of BECN1 mrnA in basal (BA), luminal (LUM), and erBB2-amplified 
(erBB2) breast cancer subclasses and normal breast tissue (n) from samples analyzed in Wang et al. 
and richardson et al. The luminal class is shown further subdivided into luminal A (LA) and luminal B 
(LB) subclasses. The mean expression of BECN1 in the total sample set is shown normalized to 0. (B) The 
relative number of samples falling into the lower, middle, and high tertiles of BECN1 gene expression in 
BA, LUM and erBB2 breast cancer subclasses in an independent set of samples from Ivshina et al. and 
Wang et al. is shown. statistically significant subclasses (*) indicating a P value < 0.05 (student t test).
to a requirement for high functional 
autophagy in ERBB2-positive breast 
tumor cells. To investigate how 
ERBB2 overexpression impacts auto-
phagy, we used stably and transiently 
ERBB2-expressing iMMEC and 
human breast cancer cell lines. First, 
BCL2-expressing, apoptosis-deficient 
Becn1+/+ iMMECs stably express-
ing EGFP-LC3B and either a human 
wild-type ERBB2 plasmid or vec-
tor control were subjected to nutri-
ent deprivation (Hanks treatment) in 
the absence or presence of the auto-
phagic flux inhibitor, bafilomycin A
1
 
(BafA1). Autophagy induction was 
quantified by fluorescence micros-
copy, as previously described.4,39,40 As 
shown in Figure 2B and C, ERBB2-
overexpressing apoptosis-deficient 
Becn1+/+ iMMECs exhibited highly 
attenuated puncta formation in 
response to nutrient deprivation com-
pared with vector-expressing Becn1+/+ 
iMMECs. This effect was observed 
even in the presence of BafA1 at a 
concentration (25 nM) that inhib-
its autophagic flux without affecting 
cell viability (Fig. S1), thus indicating 
that ERBB2 overexpression suppresses 
stress-induced autophagy in apoptosis-defective iMMECs 
(Fig. 2C, P < 0.05). This result was verified by LC3B immu-
noblotting to follow the conversion of LC3B-I to LC3B-II.41 In 
the absence of BafA1, LC3B-II increased over time in vector-
expressing Becn1+/+ iMMECs under nutrient deprivation, indi-
cating autophagy induction. In the presence of BafA1, LC3B-II 
was stabilized and displayed higher levels compared with non-
BafA1 conditions, in agreement with LC3B-II accumulation 
in association with autophagic flux inhibition. In contrast, in 
ERBB2-expressing iMMECs, total LC3B protein levels and 
LC3B-I to LC3B-II conversion, normally observed in wild-
type iMMECs under nutrient deprivation, were suppressed 
both in the absence and presence of BafA1 (Fig. 2D and E), 
thus indicating that this result was not secondary to ERBB2-
promoted acceleration of autophagic flux. The autophagy adap-
tor, SQSTM1/p62, commonly degraded during the process of 
autophagy exhibited higher protein levels in apoptosis-deficient 
ERBB2-expressing Becn1+/+ iMMECs compared with vector-
expressing Becn1+/+ iMMECs, also indicating a suppression of 
the autophagic process (Fig. 2D and E).39 The same result was 
obtained using a different metabolic stressor and quantifying 
autophagy by electron microscopy (EM). In this case, apopto-
sis-deficient Becn1+/+ iMMECs stably expressing ERBB2 under 
low (1%) oxygen and glucose-deprivation conditions showed 
decreased number of autophagosomes compared with their 
non-ERBB2-expressing Becn1+/+ counterparts (Fig. 2F and G). 
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Figure  2. stable erBB2 overexpression inhibits stress-induced autophagy in mouse mammary tumor cells. (A) Autophagy-competent Becn1+/+ and 
partially autophagy-defective Becn1+/− iMMecs were stably transfected with a human wild-type erBB2-expressing plasmid conferring resistance to 
G418. seven out of 13 Becn1+/+ G418r-colonies and 1 out of 13 Becn1+/− G418r-colonies overexpressed erBB2, as shown by erBB2 and AcTB western blots 
of whole cell protein lysates. (B) GFP-fluorescence microscopy of BcL2- and eGFP-Lc3B-expressing Becn1+/+ iMMecs, also stably expressing an erBB2 or 
vector-control plasmid, under nutrient deprivation (hanks medium) without or with bafilomycin A1 (BafA1, 25 nM). (C) Autophagy quantification of (B) 
based on number of GFP-fluorescent puncta per cell, as imaged by GFP-fluorescence microscopy. each data point is an average of triplicate experiments 
± sD after quantifying puncta in one hundred cells per experiment. **P value < 0.01. (D) GFP, sQsTM1 and AcTB western blots of whole cell protein 
lysates from apoptosis-deficient, eGFP-Lc3B-expressing, and vector- or erBB2-expressing Becn1+/+ iMMecs under nutrient deprivation without (-) and 
with (+) BafA1. erBB2-expressing iMMecs exhibited lower GFP-Lc3B expression than vector-expressing iMMecs after stable GFP-Lc3B transfection, so 
protein lysates from erBB2-expressing iMMecs were loaded at 2× the amount of vector-expressing lysates to better visualize lower GFP-Lc3B levels in 
these cells. (E) Densitometric analysis of Lc3B-II/Lc3B-I ratio and sQsTM1 protein bands, as normalized to AcTB, using ImageJ. Lc3B levels were cor-
rected for 2× loading of erBB2-expressing lysates. (F) electron micrographs of Becn1+/+ iMMecs expressing BcL2 (top row), Becn1+/+ iMMecs expressing 
BcL2 and erBB2 (middle row), and Becn1+/− iMMecs expressing BcL2 (bottom row) under metabolic stress (1% oxygen and no glucose). Images were 
taken at 3800×. White arrows indicate autophagic structures. Inlayed zoomed images show autophagosomes. (G) Autophagosome quantification of (F). 
each data point is an average of the number of autophagosomes in 25 cells ± sD. *P value < 0.05.
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Interestingly, the level of autophagy induction in metabolically 
stressed ERBB2-expressing Becn1+/+ iMMECs was similar to that 
of vector-expressing Becn1+/− iMMECs (Fig. 2F and G), confirm-
ing that ERBB2 overexpression renders mammary epithelial cells 
partially autophagy-deficient under stress.
To further investigate the impact of ERBB2 overexpression 
on stress-induced autophagy in an alternate system and in an 
apoptosis-competent background, we used a transient ERBB2 
expression system.40 To this intent, Becn1+/+ iMMECs stably 
overexpressing EGFP-LC3B were transiently transfected with a 
ERBB2-expressing or vector control plasmid and, after overnight 
recovery in regular culture medium, were incubated in Hanks 
medium for up to 3.5 h. Similar to the results described above 
(Fig. 2B–E), transient ERBB2 overexpression did not affect 
basal autophagy, but suppressed autophagy induction in wild-
type iMMECs in response to nutrient deprivation (Fig. 3A–D, 
P < 0.01). This result was confirmed by decreased LC3B-I to 
LC3B-II conversion in iMMECs transiently overexpressing 
ERBB2 in both the absence and presence of BafA1 (Fig. 3C 
and D). ERBB2 overexpression did not affect expression of the 
essential autophagy regulators BECN1 and ATG7 (Fig. S2), 
but resulted in decreased conversion of endogenous LC3B-I to 
LC3B-II (Fig. 3C), indicating that ERBB2-promoted suppres-
sion of the autophagic response to stress was not associated with 
alterations in ATG expression.
Finally, when EGFP-LC3B-expressing Becn1+/+ and Becn1+/− 
iMMECs were transiently transfected with a ERBB2-expressing 
or vector control plasmid and subjected to nutrient starvation, 
Figure 3. Transient erBB2 overexpression inhibits stress-induced autophagy in Becn1+/+ iMMecs to the level observed in partially autophagy-defec-
tive non-erBB2-expressing Becn1+/− iMMecs. (A) GFP-fluorescence microscopy of eGFP-Lc3B-expressing Becn1+/+ iMMecs transiently transfected with 
a erBB2-expressing or vector control plasmid under nutrient deprivation conditions without or with bafilomycin A1 (BafA1, 25 nM). (B) Autophagy 
quantification of (A) based on number of GFP-fluorescent puncta per cell. each data point is an average of triplicate experiments ± sD after quantifying 
puncta in 100 cells per experiment. *P value < 0.05; **P value < 0.01. (C) GFP and AcTB western blots of whole cell protein lysates from Becn1+/+ iMMecs 
transiently expressing erBB2 under nutrient deprivation without and with BafA1. (D) Densitometric analysis of Lc3B-II/Lc3B-I ratio, as normalized to 
AcTB, using ImageJ. (E) eGFP-Lc3B-expressing Becn1+/+ and Becn1+/− iMMecs transiently transfected with a erBB2-expressing or vector control plasmid 
were subjected to nutrient deprivation, and autophagy was quantified by the number of GFP-fluorescent puncta per cell. each data point is an average 
of triplicate experiments ± sD after quantifying puncta in 100 cells per experiment. *P value < 0.05; **P value < 0.01.
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ERBB2 overexpression in either Becn1+/+ or Becn1+/− iMMECs 
induced similar number of autophagic puncta to those observed 
in vector-transfected Becn1+/− iMMECs (Fig. 3E, P < 0.05), indi-
cating that ERBB2 expression rendered mammary epithelial cells 
autophagy-defective, independent of allelic Becn1 status.
The effect of ERBB2 overexpression on the functional sta-
tus of autophagy in human breast cancer cells was examined by 
transfection of stably EGFP-LC3B-expressing MCF7 cells with 
an ERBB2-expressing or vector control plasmid. Similar to the 
iMMEC results described above (Fig. 2; Fig. 3), transient ERBB2 
expression did not alter basal autophagy levels in MCF7 cells, but 
suppressed autophagy induction in response to nutrient starvation 
(Fig. 4A and B). Inhibition of autophagic flux by bafilomycin A
1
 
resulted in higher GFP puncta accumulation per cell in vector-
compared with ERBB2-expressing MCF7 cells (Fig. 4A and B, 
P < 0.05), again indicating that the ERBB2 signaling pathway 
decreases autophagy induction in response to stress and, thus, 
suggesting that ERBB2-positive breast tumors may be function-
ally autophagy-defective, independent of BECN1 expression.
To examine the effect of ERBB2 overexpression on the func-
tional status of autophagy in vivo, BCL2-, ERBB2- and EGFP-
LC3B-expressing Becn1+/+ iMMECs, as well as BCL2-expressing 
Becn1+/+ and Becn1+/− iMMECs, were orthotopically implanted 
into the mammary fat pad of nude mice. Plaques were dissected 
24 h post iMMEC implantation and LC3B translocation was 
qualitatively evaluated using fluorescence confocal microscopy. 
Similar to Figures 2D and 3E, ERBB2-overexpressing Becn1+/+ 
mammary cells exhibited similar number and size of GFP-LC3B 
puncta to Becn1+/− cells in vivo, but fewer and smaller in size 
puncta than Becn1+/+ cells (Fig. 4C).
Monoallelic Becn1 loss does not alter ERBB2- and PyMT-
driven mammary tumorigenesis
To investigate whether allelic Becn1 status impacts ERBB2-
induced mammary tumorigenesis, ERBB2-overexpressing 
Becn1+/+ and Becn1+/− iMMECs were orthotopically implanted 
in NCR nude female mice. The kinetics of allograft mammary 
tumor formation were independent of Becn1 status (Fig. 5A), 
indicating that, in our mouse mammary epithelial model,37 
monoallelic Becn1 loss does not alter ERBB2-induced mam-
mary tumorigenesis. Mammary tumors generated by ERBB2-
overexpressing Becn1+/+ and Becn1+/− iMMECs exhibited similar 
ERBB2, MKI67 (Ki67) and cleaved CASP3 levels, indicating 
that ERBB2-overexpressing Becn1+/+ and Becn1+/− iMMEC-gen-
erated tumors were similar in oncogene expression and in cell 
proliferation and death rates. However, given lower total LC3B 
expression, but similar SQSTM1 levels in Becn1+/− compared 
with Becn1+/+ tumors (Fig. 5B), differences in the functional sta-
tus of autophagy could not be reliably determined.
The functional interactions between the ERBB2 and auto-
phagy pathways were further studied by crossing Becn1+/− mice to 
2 well-characterized mouse mammary tumor models, namely the 
MMTV-Neu42 and MMTV-PyMT43 models, which show cose-
gregating tumor gene expression profiles when compared with 
other mouse mammary tumor models.44 Similar to the iMMEC 
Figure 4. Transient erBB2 overexpression inhibits stress-induced autophagy in human breast cancer cells. (A) GFP-fluorescence microscopy of eGFP-
Lc3B-expressing McF7 cells transiently transfected with a erBB2-expressing or vector control plasmid under nutrient deprivation conditions for 0, 1, 
and 2 h without and with bafilomycin A1 (BafA1, 25 nM). (B) Autophagy quantification of (A) based on number of GFP-fluorescent puncta per cell. each 
data point is an average of triplicate experiments ± sD after quantifying puncta in 100 cells per experiment. *P value < 0.05; **P value < 0.01. (C) GFP-
fluorescence confocal microscopy of tumor cell plaques dissected 24 h post orthotopic implantation of BcL2-expressing Becn1+/+ (left panel), BcL2- and 
erBB2-expressing Becn1+/+ (middle panel), and BcL2 expressing Becn1+/− (right panel) iMMecs in nude mice.
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studies described above (Fig. 5A), monoallelic Becn1 loss did not 
alter the incidence, latency or multiplicity of ERBB2-induced 
mammary tumors, independent of parity status (Fig. 6A). Similar 
ERBB2, but lower BECN1 and LC3B, levels were observed in 
Becn1+/−;MMTV-Neu compared with Becn1+/+;MMTV-Neu 
mammary glands (Fig. 6B).
It is of interest to note that the cross between Becn1+/−8 and 
MMTV-Neu mice resulted in a mixed C57BL/6:FVB (50:50) 
background and mammary tumors arose with greater latency 
and lower penetrance in Becn1+/+;MMTV-Neu mice than in the 
FVB/N MMTV-Neu model,42 in agreement with earlier reports 
that the C57BL/6 background suppresses ERBB2-induced mam-
mary tumor formation.45,46 To generate a Becn1+/− mouse model 
that is more readily amenable to mammary tumorigenesis stud-
ies, we changed the genetic background of the Becn1+/− mice 
from C57BL/68 to FVB/N. Rather than repeating the lengthier 
cross with MMTV-Neu mice, we instead crossed FVB Becn1+/− 
mice to the MMTV-PyMT mouse model, which develops mam-
mary tumors in all mammary glands within 6 to 8 wk43 and is 
frequently used as a surrogate model for ERBB2-driven mam-
mary tumorigenesis, as NEU- and PyMT-induced mammary 
tumors exhibit cosegregating gene expression signatures and high 
ERBB2 expression.47 Similar to the cross between Becn1+/− and 
MMTV-Neu mice (Fig. 6A), Becn1 heterozygosity did not 
impact PyMT-induced mammary tumorigenesis (Fig. 7A). 
Compared with Becn1+/+;MMTV-PyMT mammary tumors, 
Becn1+/−;MMTV-PyMT tumors exhibited lower BECN1 expres-
sion, but comparable ERBB2, LC3B, SQSTM1 and MKI67 
levels (Fig. 7B), indicating that cell proliferation and likely func-
tional autophagy status in PyMT-driven mammary tumors were 
not affected by monoallelic Becn1 deletion.
Autophagy inhibition enhances the response of tzb-respon-
sive human breast cancer cells to trastuzumab
Our findings that ERBB2-positive breast tumors often 
exhibit low BECN1 expression (Fig. 1), ERBB2 overexpression 
suppresses stress-induced autophagy in mammary tumor cells in 
vitro and in vivo (Figs. 2–4), and Becn1 heterozygosity does not 
impact ERBB2-induced mammary tumorigenesis in the mouse 
tumor models examined (Figs. 5–7) suggest that, in contrast 
to mutant RAS-driven tumors,38,48-50 ERBB2-overexpressing 
cancer cells do not depend on high functional autophagy levels 
for growth. It is possible, however, that the suppressed, but not 
absent, autophagic potential is still essential for ERBB2-positive 
cancer cell survival under stress and that further autophagy inhi-
bition may promote tumor cell death. To investigate this clinically 
significant hypothesis, we examined whether pharmacological 
Figure 5. erBB2-expressing Becn1+/+ and Becn1+/− iMMecs have similar tumor-forming capacities in nude mice. (A) Independent erBB2-overexpressing 
Becn1+/+ and Becn1+/− iMMec lines (e.g., A and B) were bilaterally implanted into the 3rd mammary fat pads of nude mice. Mice were monitored for 
tumor growth. each data point represents the average volume of iMMec-generated mammary tumors in 5 mice (2 tumors per mouse) per genotype 
± sD (B) representative images of erBB2, Lc3B, sQsTM1, MKI67, and cleaved cAsP3 expression, as determined by Ihc, in erBB2-expressing Becn1+/+ 
(Becn1+/+;erBB2) and erBB2-expressing Becn1+/− (Becn1+/−;erBB2) iMMec-generated allograft mammary tumors from (A).
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or genetic autophagy inhibition increased sensitivity of the 
ERBB2-positive human breast cancer cell line, BT474, to the 
humanized mouse monoclonal ERBB2 antibody trastuzumab.51 
Previous reports have shown that tzb-sensitive BT474 cancer 
cells exhibit low levels of basal autophagy and fail to upregu-
late autophagy in response to stress to the levels of other human 
breast cancer cell lines,33,52,53 further supporting our finding 
that ERBB2 overexpression suppresses autophagy. As shown in 
Figure 8A, trastuzumab inhibited BT474 cell growth at 48 and 
72 h of treatment (P < 0.05 and < 0.01, respectively), whereas 
the lysosomotropic agent and indirect autophagy inhibitor chlo-
roquine (CQ), at a concentration that blocks autophagic flux 
(25 μM, Fig. 8B and C), had minimal effect on BT474 cell 
growth. The combination of trastuzumab and CQ showed sta-
tistically significant enhanced antitumor effect relative to the 
single agent trastuzumab (Fig. 8A), indicating that pharmaco-
logical autophagy inhibition with CQ augments the therapeu-
tic efficacy of trastuzumab on tzb-sensitive BT474 breast cancer 
cells (P < 0.05). Near-complete BECN1 knockdown with siRNA 
(Fig. 8E) did not affect BT474 cell growth, but increased the 
antitumor effect of trastuzumab at 72 h (Fig. 8D, P < 0.05), 
indicating that targeted suppression of BECN1 expression also 
impacts ERBB2-positive breast cancer cell responsiveness to 
trastuzumab.
ERBB2-positive human breast tumors exhibit a low auto-
phagy gene signature independent of BECN1 mRNA status
Figure 6. Monoallelic Becn1 deletion does not affect erBB2-driven mammary tumorigenesis. (A) Kaplan-Meier curve depicting percentage of tumor-
free virgin (nulliparous-nP) mice over a period of 600 d post birth. (B) Kaplan-Meier curve depicting percentage of tumor-free retired breeder (multipa-
rous-MP) mice over a period of 600 d post birth. (C) Table summarizing tumor frequency, latency, multiplicity, and anatomical distribution per genotype. 
MG, mammary gland; slG, salivary gland. (D) representative images of hematoxylin and eosin (h&e) and erBB2, Becn1, and Lc3B expression by Ihc in 
mammary tumors from Becn1+/+;MMTV-Neu and Becn1+/−;MMTV-Neu virgin mice. Mice used: Becn1+/− (c57BL/6); MMTV-Neu (FVB/n).
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Given our initial observation that low BECN1 expression in 
human breast tumors correlates with the ERBB2 and basal-like 
subtypes in independent, but rather small, gene profiling data-
bases (Fig. 1), we examined whether this finding holds true in 
much larger and unrelated breast cancer cohorts.54-57 Tumors 
were clustered into 4 subgroups based on BECN1 expression lev-
els [high (BECN1+) vs. low (BECN1−) for BECN1 levels above 
or below the mean across samples, respectively] and reported 
ERBB2 status [positive (ERBB2+) vs. negative (ERBB2−)] and 
their expression profiles were compared regarding hormone 
receptor status, autophagy-related gene expression, and gene 
signatures of metabolic pathways (Fig. S3) previously reported 
to be affected by functional autophagy status.38,48,49,58-60 This 
analysis confirmed that ERBB2-positive and triple negative 
breast tumors commonly express low levels of BECN1 mRNA 
(Fig. 9, Fig. S4, P = 5.70E-18). We also discovered that ERBB2-
positive tumors, independent of BECN1 expression and very 
similar to non-ERBB2-expressing BECN1-low tumors, exhib-
ited low expression of autophagy-regulated genes, possibly indi-
cating functional autophagy suppression in ERBB2-positive 
breast cancers even when BECN1 is highly expressed (Fig. 9, 
Fig. S4, P = 2.60E-03). It is of great interest and worthy of 
further investigation that, similar to non-ERBB2-expressing 
BECN1-low tumors and in contrast to non-ERBB2-expressing 
BECN1-high tumors, ERBB2-positive breast tumors showed 
decreased fatty acid β-oxidation and oxidative phosphorylation 
gene signatures, independent of BECN1 expression. Intriguingly, 
ERBB2-positive breast cancers seem to have glycolysis and cell 
Figure 7. Monoallelic Becn1 loss does not impact PyMT-driven mammary tumorigenesis. (A) Kaplan-Meier curve depicting percentage of tumor-free 
virgin mice over a period of 100 d post birth. (B) Table summarizing tumor latency, multiplicity, and size. (C) representative images of h&e and erBB2, 
Becn1, Lc3B, sQsTM1, and MKI67 expression by Ihc in mammary tumors from Becn1+/+;MMTV-PyMT and Becn1+/−;MMTV-PyMT mice. Mice used: Becn1+/− 
(FVB/n); MMTV-PyMT (FVB/n).
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proliferation gene signatures between the significantly upregu-
lated and significantly downregulated patterns observed in 
non-ERBB2-expressing BECN1-low (i.e., mostly triple nega-
tive) and non-ERBB2-expressing BECN1-high (i.e., mostly hor-
mone receptor-positive) tumors, respectively (Fig. 9, Fig. S4, P = 
1.60E-05 and P = 3.10E-06).
Discussion
Role of autophagy in mammary tumorigenesis
The human epidermal growth factor receptor and tyrosine 
kinase ERBB2 has been widely studied because of its strong 
transforming potential, its role in the pathogenesis of breast can-
cer, and its use as a therapeutic target in patients with ERBB2-
positive breast tumors. ERBB2 amplification is likely an early 
genetic event in mammary tumorigenesis, as it is commonly 
observed in ductal carcinoma in situ, in the absence of invasive 
disease.61 ERBB2 status remains constant as disease progresses 
to invasive and then metastatic stages.62-65 Becn1 has been identi-
fied as a haplo-insufficient tumor suppressor, as Becn1+/− mice 
develop mammary hyperplasias, lymphomas, and lung and liver 
carcinomas, which retain a wild-type Becn1 allele.4,7 Epithelial 
cells with autophagy defects, including Becn1 heterozygosity, 
exhibit susceptibility to metabolic stress, which is accompanied 
by DNA damage and increased genomic instability, in turn 
likely driving cancer progression.4 In our study, and in agree-
ment with earlier work,14 ERBB2 overexpression and low BECN1 
mRNA levels are positively correlated in human breast cancers 
(Fig. 1), indicating that many ERBB2-positive breast malignan-
cies may be functionally autophagy-deficient. In support of this 
hypothesis, we found that ERBB2 axis activation suppresses 
stress-induced autophagy (Figs. 2–4), suggesting that ERBB2-
positive premalignant and malignant breast lesions may exhibit 
decreased autophagic potential, even if BECN1 is genomically 
intact. Given the contribution of allelic Becn1 loss to DNA dam-
age and genomic instability,4 it is conceivable that, by function-
ally suppressing autophagy, early ERBB2 activation may lead to 
further ERBB2 amplification and, thus, a positive feedback loop 
maintaining and increasing the protumorigenic function of the 
ERBB2 axis. In this case, defective autophagy, but not necessar-
ily allelic BECN1 deletion, may indeed play a role in ERBB2-
positive breast cancer, particularly during tumor initiation. 
Figure 8. Autophagy inhibition sensitizes tzb-responsive erBB2-positive breast cancer cells to trastuzumab. (A) Viability assays of BT474 cells treated 
with trastuzumab (TZB, 150 μg/ml), chloroquine (cQ, 25 μM), or combination of both for 0, 3, and 5 d. (B) Viability of BT474 after 3 d of treatment with 
increasing cQ concentrations. (C) Lc3B western blot of BT474 cells treated with increasing cQ concentrations. #middle panel is higher exposure of top 
panel (D) Viability assays of BT474 cells treated with TZB (150 μg/ml) for 0 to 3 d, starting at 24 h after transfection with BECN1 or scrambled sirnA. (E) 
Becn1 immunoblot confirms target knockdown by sirnA during 0 to 3 d of treatment. P values were calculated using paired student t test. each data 
point is an average of triplicate experiments ± sD. *P value < 0.05; **P value < 0.01.
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Recent studies support the concept that autophagy suppression 
is important for aberrant tyrosine kinase-induced tumorigenesis, 
such as those mediated by AKT1 and EGFR,66,67 which inhibit 
autophagy by phosphorylation of BECN1. Upon expression of a 
BECN1 mutant resistant to phosphorylation in cancer cell lines, 
autophagy could not be inhibited and tyrosine kinase-mediated 
xenograft tumor formation in nude mice was suppressed.66,67 It 
would be very informative to further investigate the role of auto-
phagy in ERBB2-induced tumorigenesis by generating a trans-
genic mouse model that combines ERBB2 overexpression and 
a constitutively activated or non-suppressible autophagy status. 
As it is evident from our in vitro and in vivo allograft and spon-
taneous tumorigenesis studies, unless autophagy is ectopically 
induced or engineered to be in a “nonsuppressible state,” activa-
tion of the ERBB2 axis suppresses the autophagic response to 
stress and renders ERBB2-positive breast cancer cells autophagy-
deficient, thus providing an explanation for why partial Becn1 
deficiency does not impact ERBB2-driven mammary tumor 
formation (Figs. 5–7).
Our bi-transgenic mouse models combining monoallelic 
Becn1 loss and ERBB2 or PyMT activation under the MMTV-
promoter join the efforts to study the role of defective autophagy 
in mammary tumorigenesis using mammary tumor-prone mouse 
models.68,69 In the first such publication, mammary gland-tar-
geted deletion of the positive autophagy regulator Rb1cc1/Fip200 
suppresses mammary tumor initiation and progression in the 
MMTV-PyMT model, in association with defective autophagy 
in tumor cells, as indicated by accumulation of ubiquitinated 
protein aggregates and SQSTM1, deficient LC3B conversion, 
and increased number of abnormal-appearing mitochondria.68 
In a more recently published study, monoallelic 
Becn1 loss suppresses mammary tumor formation 
driven by Palb2 deletion in mammary epithelial 
cells (MECs) in a wild-type Trp53 background, but 
fails to impact tumorigenesis induced by combined 
MEC-specific Palb2 and Trp53 loss,69 suggesting 
that the role of allelic Becn1 status in mammary 
tumorigenesis is greatly influenced by other onco-
genic events. The results mentioned above, includ-
ing our studies, once more indicate that the role of 
autophagy in breast cancer is complex and warrants 
further investigation.
Autophagy modulation for ERBB2-positive 
breast cancer treatment
Our treatment studies (Fig. 8) demonstrate that 
pharmacological inhibition of autophagy increases 
sensitivity of tzb-responsive breast cancer cells 
to trastuzumab, indicating that the functionally 
reduced autophagy status in ERBB2-overexpressing 
breast cancer cells still preserves cell viability and 
provides protection against chemotherapy. This 
finding is in agreement with previously published 
studies, which implicated autophagy in resistance 
to breast cancer treatment, as autophagy inhibition 
by CQ or silencing of Atg genes resensitized tzb-
resistant SKBR3 cells and hormone-resistant MCF7 
cells to trastuzumab and tamoxifen, respectively.33,70
Tumor cell addiction to autophagy
The suppressive effect of ERBB2 overexpression on the 
functional status of autophagy is in sharp contrast to the 
upregulation of basal autophagy and the strong dependence of 
RAS-mutant tumors on autophagy for growth.38,48-50,58 RAS-
mediated adhesion-independent transformation is dependent 
on autophagy, as autophagy inhibition reduced glycolytic 
capacity and attenuated cell proliferation and transformation.48 
Furthermore, RAS-expressing cells have high basal autophagy 
to maintain a functional mitochondrial pool and meet energy 
demands imposed by oncogenic RAS, as autophagy suppression 
decreased tumor cell survival under starvation and abrogated 
tumorigenesis in nude mice, in association with depletion of 
oxidative phosphorylation and tricarboxylic acid cycle interme-
diates.38,49 Whereas the aforementioned work38,48-50,58 suggests an 
oncogene-induced requirement for autophagy induction dur-
ing tumorigenesis, our present studies indicate that “autophagy 
addiction” is not a generalized phenomenon in cancer patho-
physiology, but its activation is instead specific to particular 
oncogenic events.
Despite the differences in autophagy functional status in 
RAS-mutant and ERBB2-positive tumors and the potentially 
discrete roles of defective autophagy in RAS- and ERBB2-
driven tumor initiation and maintenance, our studies reveal 
a common role for autophagy in resistance to cancer therapy. 
Similar to the sensitization of different tumor types to standard 
anticancer agents,13,71-73 tzb-responsive breast cancer cells were 
rendered more sensitive to trastuzumab by pharmacological and 
genetic autophagy suppression, thus further supporting use of 
Figure 9. erBB2-positive breast cancers have, independent of BECN1 expression, gene 
expression signatures similar to those of non-erBB2-expressing breast cancers with 
low BECN1 mrnA levels. The heatmap reports gene set enrichment analysis (GseA) for 
selected gene signatures (rows) in breast cancer cohorts defined by erBB2 and BECN1 
status. The color indicates the enrichment (Fischer exact test) of samples with gene sig-
nature upregulation (red, P+, enrichment < 0.05), downregulation (blue, P−, enrichment 
< 0.05), or no difference (black, P+, enrichment ≥ 0.05 and P−, enrichment ≥ 0.05) within 
a cohort subgroup relative to the remaining samples in the cohort. Gene signature 
lists and statistical analysis are provided in Figures S3 and S4, respectively. Databases: 
1) Decremoux et al. 2011, 2) hatzis et al. 2011 (erBB2-negative breast cancers only), 3) 
servant et al. 2012, and 4) sabatier et al. 2011.
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autophagy inhibitors in combination with conventional cancer 
therapies.
Autophagy functional status in ERBB2-positive breast 
tumors
Our finding that ERBB2 activation suppresses stress-induced 
autophagy in breast cancer cells in vitro and in vivo (Figs. 2–4) 
is in agreement with our analysis of human breast tumor DNA 
microarray data showing that ERBB2-expressing breast cancers 
exhibit lower expression of autophagy-related genes (Figs. S3 
and S4), independent of BECN1 expression levels (Fig. 9). It is, 
thus, likely that ERBB2-positive breast tumors are functionally 
autophagy-defective and, similar to Becn1+/− iMMECs,74 sensi-
tive to oxidative and endoplasmic reticulum (ER) stress-induc-
ing agents; this hypothesis will be investigated in subsequent 
studies.
An interesting and thought-provoking finding from our gene 
expression analysis is the striking downregulation of glycoly-
sis and proliferation gene signatures in non-ERBB2-expressing 
BECN1-high breast cancers, which are highly enriched in hor-
mone receptor-positive tumors and also exhibit high and relative 
upregulation of fatty acid β-oxidation and oxidative phosphory-
lation gene signatures, respectively. ERBB2-positive breast can-
cers, independent of BECN1 expression, are characterized by 
a relative upregulation of glycolysis and proliferation gene sig-
natures compared with non-ERBB2-expressing BECN1-high 
(mostly hormone receptor-positive) tumors, but not to levels 
observed in non-ERBB2-expressing BECN1-low (mostly triple 
negative breast) tumors. Upregulation of glycolysis in association 
with ERBB2 activation has been reported before.75-77 However, 
the high expression of glycolysis-related genes in conjunction 
with a low autophagic gene signature is surprising considering 
that, in RAS-mediated transformation, defective autophagy 
reduces glycolytic capacity.48 It is possible that breast tumors with 
high functional autophagy do not rely on glycolysis for meeting 
their metabolic demands, as fatty acid β-oxidation and oxida-
tive phosphorylation can be sustained at high levels in autoph-
agy-maintained healthy mitochondria. In contrast, low BECN1 
expression, and likely defective autophagy and deregulation of 
mitochondrial homeostasis, correlates with significant suppres-
sion of fatty acid β-oxidation and oxidative phosphorylation, as 
previously reported,38,60 thus forcing the cancer cell metabolic 
machinery toward glycolysis. The relationship between auto-
phagy regulation and metabolic reprogramming is obviously 
quite complex,58 and further studies are needed to explore the 
metabolic profiles of the different breast cancer subtypes and 
incorporate the knowledge acquired in the design of more effec-
tive therapeutic regimens.
Materials and Methods
Cell line generation and culture conditions
Primary mouse mammary epithelial cells (pMMECs) from 
Becn1+/+ and Becn1+/− mice8 were immortalized to generate 
iMMEC cell lines, which were then engineered to stably express 
BCL2, EGFP-LC3B or wild-type human ERBB2, as previously 
described.4 The BT474 (HTB-20) cell line was obtained from 
American Type Culture Collection. Hank’s balanced salt solu-
tion (Life Technologies, 14025-092) was used for nutrient-depri-
vation studies. Bafilomycin A
1
 (BafA1; Sigma-Aldrich, B1793) 
was used at a concentration of 25 nM.
Fluorescence and electron microscopy
Autophagy was quantified by quantification of EGFP-LC3B 
puncta per cell using fluorescence microscopy, using an Olympus 
IX51 fluorescent microscopy system at 60× magnification. One 
hundred cells per cell line were evaluated for number of EGFP-
LC3B puncta per cell at each time point. Three independent 
experiments were performed, and the average number of GFP-
fluorescent puncta per cell with standard deviation for each cell 
line at each time point is presented. For EM, cells were fixed 
in a 2.5% glutaraldehyde, 4% paraformaldehyde, 8 μM cal-
cium chloride, 0.1 M cacodylate, pH 7.4 fixative buffer. Electron 
microscopy was performed with a JEOL 1200EX electron micro-
scope  at 3800× magnification. Statistical analysis (2-tailed 
Student t test) was performed by Excel’s Data Analysis ToolPak 
(Microsoft, www.microsoft.com).
Western blotting and immunohistochemistry
Western blotting using whole-cell protein extracts and 
immunohistochemistry (IHC) were performed as previously 
described.78 Antibodies used were against ERBB2 (Cell Signaling, 
2165); Ki67 (Leica Microsystems, NCL-L-Ki67-MM1); LC3B 
(Novus Biologicals, NB100-2331); BECN1/Beclin1 (Santa 
Cruz Biotechnology, sc-11427); SQSTM1 (p62, Enzo Life 
Sciences, BML-PW9860); ATG7 (A2856), ACTB/β-Actin 
(Sigma-Aldrich, A4527). Cleaved CASP3 IHC was performed 
by Rutgers Cancer Institute of New Jersey Tissue Analytical 
Services. Densitometry analysis was performed by ImageJ.79
Tumorigenicity assays
Orthotopic mammary gland implantation of iMMECs4 and 
trangenic mouse tumorigenicity studies were performed accord-
ing to Institutional Animal Care and Use Committee-approved 
protocols. C57BL/6 Becn1+/− mice were crossed to MMTV-
Neu mice [FVB/N-Tg(MMTVneu) 202 Mul/J] (The Jackson 
Laboratory, 002376). To circumvent suppression of ERBB2-
induced mammary tumorigenesis by the C57BL/6 background,45 
C57BL/6 Becn1+/− mice were backcrossed into the FVB/N back-
ground for 10 generations. FVB Becn1+/− mice were subsequently 
crossed to MMTV-PyMT mice.80 Progeny cohorts of all resultant 
genotypes were observed for spontaneous mammary tumor for-
mation by weekly palpation. Kaplan-Meier survival curves and 
subsequent P values (2-tailed logrank test) were generated using 
GraphPad Prism version 5.0 for Windows (GraphPad Software, 
www.graphpad.com).
Cell viability assays
Cells were plated in 6-well plates at medium density, so as 
to ensure nonconfluency after 5 d of vehicle treatment. Media 
and drugs were changed after 3 d. Cell viability was assessed 
using the trypan blue exclusion method automated by a Vi-Cell 
(Beckman Coulter). Trastuzumab (Herceptin) was supplied 
as an aqueous solution at a concentration of 25 mg/mL and it 
was a generous gift from the Rutgers Cancer Institute of New 
Jersey clinical pharmacy. Chloroquine diphosphate salt was 
purchased from Sigma-Aldrich (C6628). Statistical analysis 
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(2-tailed Student t test) was performed by Excel’s Data Analysis 
ToolPak.
Gene expression analysis
For the data shown in Figure 1, gene expression array data 
from early stage breast cancers published by Wang et al. and by 
Richardson et al. (which included some normal breast samples) 
were combined and analyzed.35,36 The data set of Richardson 
et al., obtained on U133-Plus Affymetrix arrays, was made com-
patible with that of Wang et al., obtained on Affymetrix U133A 
arrays, by restricting it to the probe sets of the U133A chip and 
processing it with the mas5 software available at http://www.bio-
conductor.org.81 The distance-weighted discrimination method 
was used for systematic source and batch bias adjustment in the 
2 data sets.82 Breast cancers were classified into basal-like cancers 
(BA), ERBB2-positive, Luminal (LUM), Luminal A (LA) and 
Luminal B (LB) by robust consensus clustering.83 The average 
expression of each gene across all samples was normalized to 0. 
The mean relative expression of probes corresponding to gene of 
interest in each subtype was calculated and graphed. Statistical 
analysis (Student t test) was performed by Excel’s Data Analysis 
ToolPak (Microsoft, www.microsoft.com).
For the data shown in Figure 9, 4 reported breast cancer data 
sets were downloaded from Gene Expression Omnibus (GEO): 
de Cremoux et al.54 (226 breast tumors, Affymetrix U133 Plus 
2.0 Array, GEO series GSE26639), Hatzis et al.56 (508 ERBB2+ 
breast tumors, Affymetrix U133A Array, GEO series GSE25066), 
Servant et al.57 (343 breast tumors, Illumina HumanWG-6 v3.0 
expression bead chip Array, GEO series GSE30682) and Sabatier 
et al.55 (266 breast tumors, Affymetrix U133 Plus 2.0 Arrays, 
GEO series GSE21653). All the Affymetrix data sets were pro-
cessed using the justRMA function in R Bioconductor, obtaining 
a log2 expression values. For the Servant et al. data set assayed 
with an Illumina array, log2 of the reported variance stabilized 
expression values were used.57 The samples were classified into 
ERBB2-positive (ERBB2+) or ERBB2-negative (ERBB2−) based 
on the reported ERBB2 amplification status. The samples were 
classified into BECN1-high (Beclin+) or BECN1-low (Beclin-) 
depending on whether BECN1 expression (probe 208945_s_at) 
was above or below the mean across samples. Gene expression 
signatures were analyzed using Gene Set Enrichment Analysis,84 
obtaining a quantification of the statistical significance for 
upregulation (P+) or downregulation (P−) for each signature and 
sample pair. A sample was said to have a signature significantly 
upregulated if P+ < 0.05, significantly downregulated if P− < 
0.05, and no significant change otherwise. The complete lists of 
gene signatures are listed in Figure S3. Statistical analysis is listed 
in Figure S4.
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